About Foresee Pharmaceuticals
Foresee Pharmaceuticals is a company based in Taipei (Taiwan) founded in 2011. Foresee Pharmaceuticals has raised $32.5 million across 4 funding rounds from investors including CDIB Capital Group. Foresee Pharmaceuticals operates in a competitive market with competitors including Insulet, Flexion Therapeutics, Lyra Therapeutics, Cara Therapeutics and Eliem Therapeutics, among others.
- Headquarter Taipei, Taiwan
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Foresee Pharmaceuticals Co., Ltd.
-
Annual Revenue
$418.69 M114.67as on Dec 31, 2024
-
Net Profit
-$1.08 B-4.32as on Dec 31, 2024
-
EBITDA
-$999.27 M-6.99as on Dec 31, 2024
-
Total Equity Funding
$32.5 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Foresee Pharmaceuticals
Foresee Pharmaceuticals is a publicly listed company on the TPEX with ticker symbol 6576 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Foresee Pharmaceuticals
Foresee Pharmaceuticals has successfully raised a total of $32.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Foresee Pharmaceuticals
Foresee Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CDIB Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Locked | Locked | Locked |
Investor details for Foresee Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Foresee Pharmaceuticals
Investment portfolio details for Foresee Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Foresee Pharmaceuticals
Detailed financials for Foresee Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Foresee Pharmaceuticals Comparisons
Peer comparison for Foresee Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Foresee Pharmaceuticals
Foresee Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Flexion Therapeutics, Lyra Therapeutics, Cara Therapeutics and Eliem Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for ENT diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
Detailed competitors of Foresee Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Foresee Pharmaceuticals
Complete news archive for Foresee Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Foresee Pharmaceuticals
Foresee Pharmaceuticals was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Foresee Pharmaceuticals is headquartered in Taipei, Taiwan.
Foresee Pharmaceuticals is a funded company, having raised a total of $32.5M across 4 funding rounds to date.
Foresee Pharmaceuticals develops injectables and NCEs for cancer, endocrine disorders, and inflammatory diseases. Its stabilized injectable formulation platform is primarily a controlled release drug delivery platform for small molecules, peptides, and other bioactive. Its lead candidate is in phase III trials for prostate cancer, and another candidate in phase II trials for COPD and asthma. In addition, it has other candidates for acromegaly, opioid dependence, diabetic retinopathy and alport syndrome in preclinical studies. Its pipeline candidates are FP-001 (Leuprolide) for prostate cancer, FP-004 (Buprenorphine) for opioid dependence, and FP-011 (Goserelin) for the breast cancer among others.
Foresee Pharmaceuticals's top competitors include Insulet, Flexion Therapeutics and Lyra Therapeutics.
Yes, Foresee Pharmaceuticals is publicly traded on TPEX under the ticker symbol 6576.
Foresee Pharmaceuticals has 1 investor. Key investors include CDIB Capital Group.
The ticker symbol of Foresee Pharmaceuticals is 6576 on TPEX.